MX2009009982A - Nuevos anticuerpos anti-r7v humanos y usos de los mismos. - Google Patents

Nuevos anticuerpos anti-r7v humanos y usos de los mismos.

Info

Publication number
MX2009009982A
MX2009009982A MX2009009982A MX2009009982A MX2009009982A MX 2009009982 A MX2009009982 A MX 2009009982A MX 2009009982 A MX2009009982 A MX 2009009982A MX 2009009982 A MX2009009982 A MX 2009009982A MX 2009009982 A MX2009009982 A MX 2009009982A
Authority
MX
Mexico
Prior art keywords
antibodies
novel human
human anti
hiv
specifically
Prior art date
Application number
MX2009009982A
Other languages
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Original Assignee
Urrma R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39473318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009982(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urrma R & D filed Critical Urrma R & D
Publication of MX2009009982A publication Critical patent/MX2009009982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a nuevos anticuerpos humanos capaces de unirse al epítope R7V de VIH. Estos anticuerpos tienen todos CDR humanas y son capaces de neutralizar específicamente todas las cepas de VIH, incluyendo mutantes de escape. Estos anticuerpos son útiles para el tratamiento de infección por VIH, especialmente en pacientes en insuficiencia de HAART.
MX2009009982A 2007-03-22 2008-03-19 Nuevos anticuerpos anti-r7v humanos y usos de los mismos. MX2009009982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89635907P 2007-03-22 2007-03-22
PCT/EP2008/053317 WO2008113833A1 (en) 2007-03-22 2008-03-19 Novel human anti-r7v antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2009009982A true MX2009009982A (es) 2010-03-04

Family

ID=39473318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009982A MX2009009982A (es) 2007-03-22 2008-03-19 Nuevos anticuerpos anti-r7v humanos y usos de los mismos.

Country Status (18)

Country Link
US (1) US20110123536A1 (es)
EP (1) EP2137214A1 (es)
JP (1) JP2010521189A (es)
KR (1) KR20100014495A (es)
CN (1) CN101679515A (es)
AR (1) AR066396A1 (es)
AU (1) AU2008228246A1 (es)
BR (1) BRPI0808287A2 (es)
CA (1) CA2681130A1 (es)
CL (1) CL2008000820A1 (es)
IL (1) IL201034A0 (es)
MA (1) MA31256B1 (es)
MX (1) MX2009009982A (es)
RU (1) RU2009138922A (es)
TN (1) TN2009000380A1 (es)
TW (1) TW200846363A (es)
WO (1) WO2008113833A1 (es)
ZA (1) ZA200906516B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合療法
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN105020678B (zh) * 2015-08-04 2017-10-13 珠海金晟照明科技有限公司 透镜单元、透镜组件和路灯灯头
WO2017196819A2 (en) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019191079A1 (en) * 2018-03-26 2019-10-03 The University Of Chicago Methods and compositions for targeting liver and lymph node sinusoidal endothelial cell c-type lectin (lsectin)
WO2021212021A2 (en) * 2020-04-16 2021-10-21 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Also Published As

Publication number Publication date
IL201034A0 (en) 2010-05-17
CL2008000820A1 (es) 2008-08-22
AR066396A1 (es) 2009-08-19
CN101679515A (zh) 2010-03-24
EP2137214A1 (en) 2009-12-30
ZA200906516B (en) 2010-05-26
BRPI0808287A2 (pt) 2014-10-07
AU2008228246A1 (en) 2008-09-25
US20110123536A1 (en) 2011-05-26
CA2681130A1 (en) 2008-09-25
WO2008113833A1 (en) 2008-09-25
KR20100014495A (ko) 2010-02-10
RU2009138922A (ru) 2011-04-27
TW200846363A (en) 2008-12-01
MA31256B1 (fr) 2010-03-01
TN2009000380A1 (en) 2010-12-31
JP2010521189A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
TN2009000380A1 (en) Novel human anti-r7v antibodies and uses thereof
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
WO2006015035A8 (en) Useful compounds for hpv infection
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
MX340953B (es) Anticuerpos anti receptor del factor de necrosis tumoral inducido por glucocorticoides.
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
PL2126049T3 (pl) Przeciwciała przeciwko ludzkiemu wirusowi cytomegalii (HCMV)
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
TN2009000285A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
TN2010000616A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies

Legal Events

Date Code Title Description
FA Abandonment or withdrawal